Draig Therapeutics

Psychiatric-medicines biotech (two years old as of 2026) developing treatments for depression and other psychiatric conditions; secured a $65 million Series B led by Deep Track Capital, with participation from Janus Henderson Investors, Marshall Wace, and British Patient Capital.